Key result
Loss of periostin in ErbB2/Neu-driven tumors does not alter tumor initiation or growth but results in an androgen receptor-positive molecular apocrine-like tumor phenotype with reduced Notch1 activity.
Loss of periostin in an ErbB2/Neu overexpression model results in apocrine-like breast tumors that activate an androgen receptor-dependent pathway, which may have implications for therapeutic targeting.
May support AR targeting in apocrine-like tumors; leaves open human validation and clinical translation.
INTRODUCTION: Periostin (Postn) is a secreted cell adhesion protein that activates signaling pathways to promote cancer cell survival, angiogenesis, invasion, and metastasis. Interestingly, Postn is frequently overexpressed in numerous human cancers, including breast, lung, colon, pancreatic, and ovarian cancer. METHODS: Using transgenic mice expressing the Neu oncogene in the mammary epithelium crossed into Postn-deficient animals, we have assessed the effect of Postn gene deletion on Neu-driven mammary tumorigenesis. RESULTS: Although Postn is exclusively expressed in the stromal fibroblasts of the mammary gland, Postn deletion does not affect mammary gland outgrowth during development or pregnancy. Furthermore, we find that loss of Postn in the mammary epithelium does not alter breast tumor initiation or growth in mouse mammary tumor virus (MMTV)-Neu expressing mice but results in an apocrine-like tumor phenotype. Surprisingly, we find that tumors derived from Postn-null animals express low levels of Notch protein and Hey1 mRNA but increased expression of androgen receptor (AR) and AR target genes. We show that tumor cells derived from wild-type animals do not proliferate when transplanted in a Postn-null environment but that this growth defect is rescued by the overexpression of active Notch or the AR target gene prolactin-induced protein (PIP/GCDFP-15). CONCLUSIONS: Together our data suggest that loss of Postn in an ErbB2/Neu/HER2 overexpression model results in apocrine-like tumors that activate an AR-dependent pathway. This may have important implications for the treatment of breast cancers involving the therapeutic targeting of periostin or Notch signaling.
No takes yet. Share an insight, caveat, or question.
Sriram et al. (2015) studied ErbB2/Neu-driven breast cancer. Periostin (Postn) gene deletion vs. Wild-type Postn was evaluated on Mammary tumor initiation and growth. Loss of periostin in ErbB2/Neu-driven tumors does not alter tumor initiation or growth but results in an androgen receptor-positive molecular apocrine-like tumor phenotype with reduced Notch1 activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: